Advertisement

Retinal Vein Occlusion

  • Ute E. K. Wolf-Schnurrbusch
Chapter

Abstract

Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are retinal vascular diseases that may cause significant ocular morbidity and vision loss (David et al. 1988; Rogers et al. 2010). It commonly affects men and women equally and occurs predominantly in the age of 65 years (Lang and Handel 1992; Noma et al. 2005 and 2008; Chen et al. 1995; Iturralde et al. 2006). Younger individuals which present with a clinical picture of CRVO may have an underlying inflammatory etiology (Fekrat and Finkelstein 1999). Most common risk factors associated with CRVO and BRVO are systemic hypertension, diabetes, hyperlipidemia, glaucoma, carotid insufficiency, smoking, and age-related atherosclerosis (Noma et al. 2005; Sunness et al. 1991). Other associated factors are listed in Table 11.1.

Keywords

Macular Edema Optic Nerve Head Retinal Vein Occlusion Central Retinal Vein Occlusion Branch Retinal Vein Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bandello F, Tavola A, Pierro L (1998) Axial length and refraction in retinal vein occlusions. Ophthalmologica 212:133–135CrossRefPubMedGoogle Scholar
  2. Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245–252CrossRefPubMedGoogle Scholar
  3. Central Retinal Vein Occlusion Study Group (1993) Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group. Online J Curr Clin Trials Doc No 95.Google Scholar
  4. Chen JC, Klein ML, Watzke RC, Handelman IL, Robertson JE (1995) Natural course of perfused central retinal vein occlusion. Can J Ophthalmol 30:21–24PubMedGoogle Scholar
  5. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149CrossRefPubMedGoogle Scholar
  6. David R, Zangwill L, Badarna M, Yassur Y (1988) Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197:69–74CrossRefPubMedGoogle Scholar
  7. Fekrat S, Finkelstein D (1999) Venous occlusive disease. In: Regillo CD, Brown GC, Flynn HW (eds) Vitreoretinal disease: the essentials, 1st edn. Thieme, New YorkGoogle Scholar
  8. Green W, Chan C, Hutchins G (1981) Central retinal vein occlusions: a prospective histopathologic study of 29 eyes in 28 cases. Retina 1:27–55PubMedGoogle Scholar
  9. Iturralde D, Spaide RF, Meyerle CB (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMedGoogle Scholar
  10. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal Triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758PubMedGoogle Scholar
  11. Klein ML, Finkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297–1302CrossRefPubMedGoogle Scholar
  12. Lang GE, Handel A (1992) Clinical and fluorescein angiography changes in patients with central retinal vein occlusion. A unicenter study of 125 patients. Klin Monbl Augenheilkd 201:302–308CrossRefPubMedGoogle Scholar
  13. Noma H, Funatsu H, Yamasaki M et al (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261CrossRefPubMedGoogle Scholar
  14. Noma H, Funatsu H, Mimura T, Hori S (2008) Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 18:1017–1019PubMedGoogle Scholar
  15. Priglinger SG, Wolf AH, Kreutzer TC (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012CrossRefPubMedGoogle Scholar
  16. Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRefPubMedPubMedCentralGoogle Scholar
  17. Sunness JS, Gass JDM, Singerman U (1991) Retinal and choroidal changes in pregnancy. In: Singerman U, Jampol LM (eds) Retinal and choroidal manifestations of systemic disease. Baltimore, Wiliams & WiliamsGoogle Scholar
  18. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 98:271–282CrossRefGoogle Scholar
  19. Wolf-Schnurrbusch UEK, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S (2011) Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 52:3334–3337CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity Hospital Bern, Inselspital, University BernBernSwitzerland

Personalised recommendations